☆ 4.7 Letter

Assessment of Median and Mean Survival Time in Cancer Clinical Trials

JAMA NETWORK OPEN (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations

Zachary R. McCaw et al.

Summary: When designing comparative oncology trials, the treatment effect is often quantified as a difference in median survival times and converted to a hazard ratio for determining study size. However, the hazard ratio may be difficult to interpret clinically and the medians cannot capture all differences, leading to inconsistent conclusions about the treatment effect.

JNCI CANCER SPECTRUM (2022)

Add to Collection

Letter Oncology

Transparency in reporting of phase 3 cancer clinical trial results

Roshal R. Patel et al.

ACTA ONCOLOGICA (2021)

Add to Collection

Article Oncology

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Omer Ben-Aharon et al.

ONCOLOGIST (2019)

Add to Collection

Article Oncology

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

Hajime Uno et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Health Care Sciences & Services

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Patricia Guyot et al.

BMC MEDICAL RESEARCH METHODOLOGY (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.